Current progress of siRNA/shRNA therapeutics in clinical trials
- 11 July 2011
- journal article
- review article
- Published by Wiley in Biotechnology Journal
- Vol. 6 (9), 1130-1146
- https://doi.org/10.1002/biot.201100054
Abstract
Through a mechanism known as RNA interference (RNAi), small interfering RNA (siRNA) molecules can target complementary mRNA strands for degradation, thus specifically inhibiting gene expression. The ability of siRNAs to inhibit gene expression offers a mechanism that can be exploited for novel therapeutics. Indeed, over the past decade, at least 21 siRNA therapeutics have been developed for more than a dozen diseases, including various cancers, viruses, and genetic disorders. Like other biological drugs, RNAi‐based therapeutics often require a delivery vehicle to transport them to the targeted cells. Thus, the clinical advancement of numerous siRNA drugs has relied on the development of siRNA carriers, including biodegradable nanoparticles, lipids, bacteria, and attenuated viruses. Most therapies permit systemic delivery of the siRNA drug, while others use ex vivo delivery by autologous cell therapy. Advancements in bioengineering and nanotechnology have led to improved control of delivery and release of some siRNA therapeutics. Likewise, progress in molecular biology has allowed for improved design of the siRNA molecules. Here, we provide an overview of siRNA therapeutics in clinical trials, including their clinical progress, the challenges they have encountered, and the future they hold in the treatment of human diseases.Keywords
This publication has 99 references indexed in Scilit:
- RNAi and small interfering RNAs in human disease therapeutic applicationsTrends in Biotechnology, 2010
- HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL)Transplantation and Cellular Therapy, 2010
- Clinical status of duplex RNABioorganic & Medicinal Chemistry Letters, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin DisorderMolecular Therapy, 2010
- RNAi‐based therapeutics–current status, challenges and prospectsEMBO Molecular Medicine, 2009
- Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growthProceedings of the National Academy of Sciences of the United States of America, 2009
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacyNature Biotechnology, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003